Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update
Pyxis Oncology, Inc. (Nasdaq: PYXS) reported its third-quarter financial results for 2021, highlighting a strong cash position of approximately $283 million, expected to fund operations into late 2024. The company completed its IPO in October 2021, raising $168 million. R&D expenses surged to $7.8 million due to increased activities and personnel, while G&A expenses rose to $3.8 million. The net loss for the quarter was $14.2 million, or $8.96 per share, compared to a loss of $3.2 million in Q3 2020. The company aims to submit IND applications for its lead programs by 2022 and 2023.
- Strong cash position of approximately $283 million, funding operations into late 2024.
- Completed IPO in October 2021, raising $168 million in gross proceeds.
- Net loss increased to $14.2 million in Q3 2021, compared to $3.2 million in Q3 2020.
- R&D expenses increased significantly, reaching $7.8 million, indicating higher operational costs.
CAMBRIDGE, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its third quarter ended September 30, 2021 and provided a business update.
“Our initial public offering was a tremendous milestone for Pyxis, allowing us to debut as a public company with a strong balance sheet well positioned to advance our lead programs toward the clinic,” said Lara Sullivan, M.D., Chief Executive Officer of Pyxis. “We are on track to submit Investigational New Drug (IND) applications for PYX-201 and PYX-202 by mid-2022, and for PYX-203 by 2023. With the resources we now have in hand, we are also focused on fully leveraging our ADC technology platform and proprietary target catalog.”
Initial Public Offering (IPO)
In October 2021, Pyxis completed its IPO of 10,500,000 shares of common stock at a public offering price of
Third Quarter 2021 Financial Results
Cash: Pyxis has a strong cash position of approximately
Research and Development (R&D) Expenses: R&D expenses were
General and Administrative (G&A) Expenses: G&A expenses were
Net Loss: Net loss was
Upcoming Investor Event
- November 18, 2021 – Pyxis will present at the Jefferies Virtual London Healthcare Conference
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. Pyxis develops its product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis visit www.pyxisoncology.com.
Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “to be,” “will,” “would,” or the negative or plural of these words, or similar expressions or variations, although not all forward-looking statements contain these words. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified herein, and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company's most recent Quarterly Report on Form 10-Q and in our other filings with the SEC. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form 10-Q, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.
PYXIS ONCOLOGY, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | $ | 7,849 | $ | 2,425 | $ | 43,828 | $ | 5,909 | ||||||||
| General and administrative | 3,772 | 767 | 9,463 | 2,406 | ||||||||||||
| Total operating expenses | 11,621 | 3,192 | 53,291 | 8,315 | ||||||||||||
| Loss from operations | (11,621 | ) | (3,192 | ) | (53,291 | ) | (8,315 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 6 | 1 | 16 | 66 | ||||||||||||
| Service fee income from related party | — | — | 181 | — | ||||||||||||
| Change in fair value of derivative liability | (2,560 | ) | — | (5,821 | ) | — | ||||||||||
| Total other income (expense) | (2,554 | ) | 1 | (5,624 | ) | 66 | ||||||||||
| Loss from equity method investment in joint venture | — | — | (231 | ) | — | |||||||||||
| Net loss and comprehensive loss | $ | (14,175 | ) | $ | (3,191 | ) | $ | (59,146 | ) | $ | (8,249 | ) | ||||
| Net loss per common share, basic and diluted | $ | (8.96 | ) | $ | (2.93 | ) | $ | (40.27 | ) | $ | (8.43 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 1,581,610 | 1,088,222 | 1,468,777 | 979,081 | ||||||||||||
PYXIS ONCOLOGY, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
(Unaudited)
| September 30, 2021 | December 31, 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 133,477 | $ | 8,080 | ||||
| Prepaid expenses and other current assets | 859 | 23 | ||||||
| Total current assets | 134,336 | 8,103 | ||||||
| Property and equipment, net | 1,154 | 1,103 | ||||||
| Operating lease right-of-use assets | 388 | 836 | ||||||
| Deferred offering costs | 3,501 | — | ||||||
| Other assets, noncurrent | 109 | 109 | ||||||
| Total assets | $ | 139,488 | $ | 10,151 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,927 | $ | 1,077 | ||||
| Accrued expenses and other current liabilities | 5,462 | 1,997 | ||||||
| Derivative liability, current portion | 9,123 | — | ||||||
| Operating lease liabilities, current portion | 325 | 615 | ||||||
| Total current liabilities | 16,837 | 3,689 | ||||||
| Derivative liability, net of current portion | 67 | — | ||||||
| Operating lease liabilities, net of current portion | — | 165 | ||||||
| Total liabilities | 16,904 | 3,854 | ||||||
| Commitments and contingencies | ||||||||
| Series A Convertible Preferred Stock | 21,942 | 21,942 | ||||||
| Series B Convertible Preferred Stock | 172,081 | — | ||||||
| Stockholders’ deficit: | ||||||||
| Common stock | 2 | 1 | ||||||
| Additional paid-in capital | 3,448 | 97 | ||||||
| Accumulated deficit | (74,889 | ) | (15,743 | ) | ||||
| Total stockholders’ deficit | (71,439 | ) | (15,645 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 139,488 | $ | 10,151 | ||||
Investor and Media Contact
Courtney Dugan
Vice President - Investor Relations
ir@pyxisoncology.com
FAQ
What were the financial results for Pyxis Oncology for Q3 2021?
When does Pyxis plan to submit IND applications for its therapeutic programs?
How much capital did Pyxis raise during its IPO?
What is the current cash position of Pyxis Oncology?
